Ontology type: schema:ScholarlyArticle Open Access: True
2008-01-15
AUTHORSPer-Göran Larsson, Babill Stray-Pedersen, Kjeld R Ryttig, Stig Larsen
ABSTRACTBackgroundThe primary objective of this study was to investigate if supplementary lactobacilli treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial cure.MethodsWomen (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial.ResultsThe initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears at the initial visit who continued the study and whose next smear indicated a cure was included in the cured group; the study also excluded two of the patients in the lactobacilli group who reported that they did not take any vaginal capsules. With consideration to these population changes, the initial cure rate would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two groups regarding "Time from cure to relapse" was statistically significant (p = 0.027) in favour of the lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse with a proportional Hazard Risk ratio (HR) of 0.73 (0.54–0.98) (p < 0.05)ConclusionThe study shows that supplementary treatment combining two different strains of probiotic lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse significantly in that more women remained BV free at the end of the 6-month follow up.Trial registration numberISRCTN62879834 More... »
PAGES3
http://scigraph.springernature.com/pub.10.1186/1472-6874-8-3
DOIhttp://dx.doi.org/10.1186/1472-6874-8-3
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1005792714
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/18197974
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Administration, Intravaginal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Administration, Oral",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Anti-Bacterial Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Clindamycin",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Combined Modality Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Confidence Intervals",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Double-Blind Method",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Follow-Up Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Lactobacillus",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Norway",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Odds Ratio",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Probiotics",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Secondary Prevention",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Vagina",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Vaginosis, Bacterial",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Women's Health",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Obstetrics and Gynaecology, K\u00e4rnsjukhuset, SE-541 85, Sk\u00f6vde, Sweden",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Obstetrics and Gynaecology, K\u00e4rnsjukhuset, SE-541 85, Sk\u00f6vde, Sweden"
],
"type": "Organization"
},
"familyName": "Larsson",
"givenName": "Per-G\u00f6ran",
"id": "sg:person.012634564012.84",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012634564012.84"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway",
"id": "http://www.grid.ac/institutes/grid.5510.1",
"name": [
"Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway"
],
"type": "Organization"
},
"familyName": "Stray-Pedersen",
"givenName": "Babill",
"id": "sg:person.0631122174.01",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631122174.01"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Farmaservice, DK-2990, Niv\u00e5, Denmark",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Farmaservice, DK-2990, Niv\u00e5, Denmark"
],
"type": "Organization"
},
"familyName": "Ryttig",
"givenName": "Kjeld R",
"id": "sg:person.010725643124.05",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010725643124.05"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Norwegian School of Veterinary Science, also Ullev\u00e5l University Hospital, Oslo, Norway",
"id": "http://www.grid.ac/institutes/grid.19477.3c",
"name": [
"Norwegian School of Veterinary Science, also Ullev\u00e5l University Hospital, Oslo, Norway"
],
"type": "Organization"
},
"familyName": "Larsen",
"givenName": "Stig",
"id": "sg:person.013272512512.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013272512512.34"
],
"type": "Person"
}
],
"datePublished": "2008-01-15",
"datePublishedReg": "2008-01-15",
"description": "BackgroundThe primary objective of this study was to investigate if supplementary lactobacilli treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial cure.MethodsWomen (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial.ResultsThe initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears at the initial visit who continued the study and whose next smear indicated a cure was included in the cured group; the study also excluded two of the patients in the lactobacilli group who reported that they did not take any vaginal capsules. With consideration to these population changes, the initial cure rate would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two groups regarding \"Time from cure to relapse\" was statistically significant (p = 0.027) in favour of the lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse with a proportional Hazard Risk ratio (HR) of 0.73 (0.54\u20130.98) (p < 0.05)ConclusionThe study shows that supplementary treatment combining two different strains of probiotic lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse significantly in that more women remained BV free at the end of the 6-month follow up.Trial registration numberISRCTN62879834",
"genre": "article",
"id": "sg:pub.10.1186/1472-6874-8-3",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1028438",
"issn": [
"1472-6874"
],
"name": "BMC Women's Health",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "8"
}
],
"keywords": [
"hazard risk ratio",
"initial cure rate",
"menstrual cycle",
"cure rate",
"Lactobacillus treatment",
"clindamycin therapy",
"adjunct treatment",
"bacterial vaginosis",
"Lactobacillus group",
"identical placebo capsules",
"avoidance of relapse",
"placebo-controlled trial",
"placebo-controlled study",
"placebo capsules",
"placebo group",
"adjuvant therapy",
"initial visit",
"BV therapy",
"recurrence rate",
"Amsel criteria",
"risk ratio",
"vaginal capsules",
"supplementary treatment",
"therapy",
"first month",
"informed consent",
"relapse",
"patients",
"initial cure",
"women",
"more women",
"gelatine capsules",
"treatment",
"probiotic lactobacilli",
"vaginosis",
"cure",
"human lactobacilli",
"smears",
"Lactobacillus",
"capsule",
"primary objective",
"group",
"different strains",
"placebo",
"MethodsWomen",
"clindamycin",
"follow",
"study",
"trials",
"visits",
"supplementation",
"months",
"study show",
"efficacy",
"rate",
"initial intent",
"consent",
"days",
"time",
"criteria",
"intent",
"end",
"cycle",
"avoidance",
"strains",
"changes",
"BV",
"objective",
"favor",
"ratio",
"time span",
"comparison",
"analysis",
"span",
"consideration",
"population change",
"show"
],
"name": "Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study",
"pagination": "3",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1005792714"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/1472-6874-8-3"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"18197974"
]
}
],
"sameAs": [
"https://doi.org/10.1186/1472-6874-8-3",
"https://app.dimensions.ai/details/publication/pub.1005792714"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T16:58",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_469.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/1472-6874-8-3"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'
This table displays all metadata directly associated to this object as RDF triples.
246 TRIPLES
20 PREDICATES
122 URIs
114 LITERALS
27 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1186/1472-6874-8-3 | schema:about | N00a61968459a45709af0a7a164059d91 |
2 | ″ | ″ | N00db1f247225430c8e22f16fa9174fb7 |
3 | ″ | ″ | N1e010c6039314b269700860fded61c7d |
4 | ″ | ″ | N2416aa67cab04e3bb9929460c34f3abe |
5 | ″ | ″ | N44de9aa8ed6f4951a71e705962c7068e |
6 | ″ | ″ | N479979b8fe974388a63afdd34340756a |
7 | ″ | ″ | N4c240cb674ea4d9b88ae2a4aac550968 |
8 | ″ | ″ | N66eef0127cac4b069ce79e53945ebf4c |
9 | ″ | ″ | N7517a1ea74f94e9586fa65ffea616522 |
10 | ″ | ″ | N79a98e9fd8b241cbabc2e8f2aac923ee |
11 | ″ | ″ | N7b9fef69ca97421190fe1e8e1d61ba75 |
12 | ″ | ″ | N7e0dc1743c1b4dafacbd08a10dd81c80 |
13 | ″ | ″ | N9033fc8f16b84dca9287e394c86348fa |
14 | ″ | ″ | N90837c2d6ada4283974cfacb3937916b |
15 | ″ | ″ | N91c550acd6464b4db288b99da9e59581 |
16 | ″ | ″ | N9a534861d9414199956c4012f44d4faf |
17 | ″ | ″ | Naf5a25a3e88c43f5a552633786bc7d40 |
18 | ″ | ″ | Nb25845f70db445f9b5f6997642756eb4 |
19 | ″ | ″ | Nb5f4cd90797044a5933666334a01b390 |
20 | ″ | ″ | Nc7ae757080304eb2a04a86772cbd69dd |
21 | ″ | ″ | anzsrc-for:11 |
22 | ″ | ″ | anzsrc-for:1103 |
23 | ″ | schema:author | Nf682a0df54c24ae699508adff64980d1 |
24 | ″ | schema:datePublished | 2008-01-15 |
25 | ″ | schema:datePublishedReg | 2008-01-15 |
26 | ″ | schema:description | BackgroundThe primary objective of this study was to investigate if supplementary lactobacilli treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial cure.MethodsWomen (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial.ResultsThe initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears at the initial visit who continued the study and whose next smear indicated a cure was included in the cured group; the study also excluded two of the patients in the lactobacilli group who reported that they did not take any vaginal capsules. With consideration to these population changes, the initial cure rate would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two groups regarding "Time from cure to relapse" was statistically significant (p = 0.027) in favour of the lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse with a proportional Hazard Risk ratio (HR) of 0.73 (0.54–0.98) (p < 0.05)ConclusionThe study shows that supplementary treatment combining two different strains of probiotic lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse significantly in that more women remained BV free at the end of the 6-month follow up.Trial registration numberISRCTN62879834 |
27 | ″ | schema:genre | article |
28 | ″ | schema:isAccessibleForFree | true |
29 | ″ | schema:isPartOf | Nb2b488dd50494ead86b0369bd9eeedcf |
30 | ″ | ″ | Nfed393813e0340dfac4f13f42cd2c4d9 |
31 | ″ | ″ | sg:journal.1028438 |
32 | ″ | schema:keywords | Amsel criteria |
33 | ″ | ″ | BV |
34 | ″ | ″ | BV therapy |
35 | ″ | ″ | Lactobacillus |
36 | ″ | ″ | Lactobacillus group |
37 | ″ | ″ | Lactobacillus treatment |
38 | ″ | ″ | MethodsWomen |
39 | ″ | ″ | adjunct treatment |
40 | ″ | ″ | adjuvant therapy |
41 | ″ | ″ | analysis |
42 | ″ | ″ | avoidance |
43 | ″ | ″ | avoidance of relapse |
44 | ″ | ″ | bacterial vaginosis |
45 | ″ | ″ | capsule |
46 | ″ | ″ | changes |
47 | ″ | ″ | clindamycin |
48 | ″ | ″ | clindamycin therapy |
49 | ″ | ″ | comparison |
50 | ″ | ″ | consent |
51 | ″ | ″ | consideration |
52 | ″ | ″ | criteria |
53 | ″ | ″ | cure |
54 | ″ | ″ | cure rate |
55 | ″ | ″ | cycle |
56 | ″ | ″ | days |
57 | ″ | ″ | different strains |
58 | ″ | ″ | efficacy |
59 | ″ | ″ | end |
60 | ″ | ″ | favor |
61 | ″ | ″ | first month |
62 | ″ | ″ | follow |
63 | ″ | ″ | gelatine capsules |
64 | ″ | ″ | group |
65 | ″ | ″ | hazard risk ratio |
66 | ″ | ″ | human lactobacilli |
67 | ″ | ″ | identical placebo capsules |
68 | ″ | ″ | informed consent |
69 | ″ | ″ | initial cure |
70 | ″ | ″ | initial cure rate |
71 | ″ | ″ | initial intent |
72 | ″ | ″ | initial visit |
73 | ″ | ″ | intent |
74 | ″ | ″ | menstrual cycle |
75 | ″ | ″ | months |
76 | ″ | ″ | more women |
77 | ″ | ″ | objective |
78 | ″ | ″ | patients |
79 | ″ | ″ | placebo |
80 | ″ | ″ | placebo capsules |
81 | ″ | ″ | placebo group |
82 | ″ | ″ | placebo-controlled study |
83 | ″ | ″ | placebo-controlled trial |
84 | ″ | ″ | population change |
85 | ″ | ″ | primary objective |
86 | ″ | ″ | probiotic lactobacilli |
87 | ″ | ″ | rate |
88 | ″ | ″ | ratio |
89 | ″ | ″ | recurrence rate |
90 | ″ | ″ | relapse |
91 | ″ | ″ | risk ratio |
92 | ″ | ″ | show |
93 | ″ | ″ | smears |
94 | ″ | ″ | span |
95 | ″ | ″ | strains |
96 | ″ | ″ | study |
97 | ″ | ″ | study show |
98 | ″ | ″ | supplementary treatment |
99 | ″ | ″ | supplementation |
100 | ″ | ″ | therapy |
101 | ″ | ″ | time |
102 | ″ | ″ | time span |
103 | ″ | ″ | treatment |
104 | ″ | ″ | trials |
105 | ″ | ″ | vaginal capsules |
106 | ″ | ″ | vaginosis |
107 | ″ | ″ | visits |
108 | ″ | ″ | women |
109 | ″ | schema:name | Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study |
110 | ″ | schema:pagination | 3 |
111 | ″ | schema:productId | N3642e0ebb21040538bd6b3e426b28315 |
112 | ″ | ″ | N89530cb1042548e38fd4e36680b7bee9 |
113 | ″ | ″ | Ncc6bce085a9d490ea1ed98f92606f4b8 |
114 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1005792714 |
115 | ″ | ″ | https://doi.org/10.1186/1472-6874-8-3 |
116 | ″ | schema:sdDatePublished | 2022-08-04T16:58 |
117 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
118 | ″ | schema:sdPublisher | Nba3387338ea246f3b2cb92c7d2fd720c |
119 | ″ | schema:url | https://doi.org/10.1186/1472-6874-8-3 |
120 | ″ | sgo:license | sg:explorer/license/ |
121 | ″ | sgo:sdDataset | articles |
122 | ″ | rdf:type | schema:ScholarlyArticle |
123 | N00a61968459a45709af0a7a164059d91 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
124 | ″ | schema:name | Follow-Up Studies |
125 | ″ | rdf:type | schema:DefinedTerm |
126 | N00db1f247225430c8e22f16fa9174fb7 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
127 | ″ | schema:name | Vaginosis, Bacterial |
128 | ″ | rdf:type | schema:DefinedTerm |
129 | N1e010c6039314b269700860fded61c7d | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
130 | ″ | schema:name | Norway |
131 | ″ | rdf:type | schema:DefinedTerm |
132 | N204afa7100d64c7ab6f6164fca5b1798 | rdf:first | sg:person.0631122174.01 |
133 | ″ | rdf:rest | N94e1213285e64b3aa065fc508925a65b |
134 | N2416aa67cab04e3bb9929460c34f3abe | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
135 | ″ | schema:name | Adult |
136 | ″ | rdf:type | schema:DefinedTerm |
137 | N3642e0ebb21040538bd6b3e426b28315 | schema:name | dimensions_id |
138 | ″ | schema:value | pub.1005792714 |
139 | ″ | rdf:type | schema:PropertyValue |
140 | N44de9aa8ed6f4951a71e705962c7068e | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
141 | ″ | schema:name | Confidence Intervals |
142 | ″ | rdf:type | schema:DefinedTerm |
143 | N479979b8fe974388a63afdd34340756a | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
144 | ″ | schema:name | Administration, Oral |
145 | ″ | rdf:type | schema:DefinedTerm |
146 | N4c240cb674ea4d9b88ae2a4aac550968 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
147 | ″ | schema:name | Clindamycin |
148 | ″ | rdf:type | schema:DefinedTerm |
149 | N66eef0127cac4b069ce79e53945ebf4c | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
150 | ″ | schema:name | Lactobacillus |
151 | ″ | rdf:type | schema:DefinedTerm |
152 | N7517a1ea74f94e9586fa65ffea616522 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
153 | ″ | schema:name | Probiotics |
154 | ″ | rdf:type | schema:DefinedTerm |
155 | N79a98e9fd8b241cbabc2e8f2aac923ee | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
156 | ″ | schema:name | Administration, Intravaginal |
157 | ″ | rdf:type | schema:DefinedTerm |
158 | N7b9fef69ca97421190fe1e8e1d61ba75 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
159 | ″ | schema:name | Female |
160 | ″ | rdf:type | schema:DefinedTerm |
161 | N7e0dc1743c1b4dafacbd08a10dd81c80 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
162 | ″ | schema:name | Middle Aged |
163 | ″ | rdf:type | schema:DefinedTerm |
164 | N89530cb1042548e38fd4e36680b7bee9 | schema:name | pubmed_id |
165 | ″ | schema:value | 18197974 |
166 | ″ | rdf:type | schema:PropertyValue |
167 | N9033fc8f16b84dca9287e394c86348fa | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
168 | ″ | schema:name | Double-Blind Method |
169 | ″ | rdf:type | schema:DefinedTerm |
170 | N90837c2d6ada4283974cfacb3937916b | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
171 | ″ | schema:name | Humans |
172 | ″ | rdf:type | schema:DefinedTerm |
173 | N91c550acd6464b4db288b99da9e59581 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
174 | ″ | schema:name | Secondary Prevention |
175 | ″ | rdf:type | schema:DefinedTerm |
176 | N94e1213285e64b3aa065fc508925a65b | rdf:first | sg:person.010725643124.05 |
177 | ″ | rdf:rest | Nb5f524ba2e27458c83db25e6c21ec432 |
178 | N9a534861d9414199956c4012f44d4faf | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
179 | ″ | schema:name | Odds Ratio |
180 | ″ | rdf:type | schema:DefinedTerm |
181 | Naf5a25a3e88c43f5a552633786bc7d40 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
182 | ″ | schema:name | Anti-Bacterial Agents |
183 | ″ | rdf:type | schema:DefinedTerm |
184 | Nb25845f70db445f9b5f6997642756eb4 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
185 | ″ | schema:name | Women's Health |
186 | ″ | rdf:type | schema:DefinedTerm |
187 | Nb2b488dd50494ead86b0369bd9eeedcf | schema:issueNumber | 1 |
188 | ″ | rdf:type | schema:PublicationIssue |
189 | Nb5f4cd90797044a5933666334a01b390 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
190 | ″ | schema:name | Vagina |
191 | ″ | rdf:type | schema:DefinedTerm |
192 | Nb5f524ba2e27458c83db25e6c21ec432 | rdf:first | sg:person.013272512512.34 |
193 | ″ | rdf:rest | rdf:nil |
194 | Nba3387338ea246f3b2cb92c7d2fd720c | schema:name | Springer Nature - SN SciGraph project |
195 | ″ | rdf:type | schema:Organization |
196 | Nc7ae757080304eb2a04a86772cbd69dd | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
197 | ″ | schema:name | Combined Modality Therapy |
198 | ″ | rdf:type | schema:DefinedTerm |
199 | Ncc6bce085a9d490ea1ed98f92606f4b8 | schema:name | doi |
200 | ″ | schema:value | 10.1186/1472-6874-8-3 |
201 | ″ | rdf:type | schema:PropertyValue |
202 | Nf682a0df54c24ae699508adff64980d1 | rdf:first | sg:person.012634564012.84 |
203 | ″ | rdf:rest | N204afa7100d64c7ab6f6164fca5b1798 |
204 | Nfed393813e0340dfac4f13f42cd2c4d9 | schema:volumeNumber | 8 |
205 | ″ | rdf:type | schema:PublicationVolume |
206 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
207 | ″ | schema:name | Medical and Health Sciences |
208 | ″ | rdf:type | schema:DefinedTerm |
209 | anzsrc-for:1103 | schema:inDefinedTermSet | anzsrc-for: |
210 | ″ | schema:name | Clinical Sciences |
211 | ″ | rdf:type | schema:DefinedTerm |
212 | sg:journal.1028438 | schema:issn | 1472-6874 |
213 | ″ | schema:name | BMC Women's Health |
214 | ″ | schema:publisher | Springer Nature |
215 | ″ | rdf:type | schema:Periodical |
216 | sg:person.010725643124.05 | schema:affiliation | grid-institutes:None |
217 | ″ | schema:familyName | Ryttig |
218 | ″ | schema:givenName | Kjeld R |
219 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010725643124.05 |
220 | ″ | rdf:type | schema:Person |
221 | sg:person.012634564012.84 | schema:affiliation | grid-institutes:None |
222 | ″ | schema:familyName | Larsson |
223 | ″ | schema:givenName | Per-Göran |
224 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012634564012.84 |
225 | ″ | rdf:type | schema:Person |
226 | sg:person.013272512512.34 | schema:affiliation | grid-institutes:grid.19477.3c |
227 | ″ | schema:familyName | Larsen |
228 | ″ | schema:givenName | Stig |
229 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013272512512.34 |
230 | ″ | rdf:type | schema:Person |
231 | sg:person.0631122174.01 | schema:affiliation | grid-institutes:grid.5510.1 |
232 | ″ | schema:familyName | Stray-Pedersen |
233 | ″ | schema:givenName | Babill |
234 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631122174.01 |
235 | ″ | rdf:type | schema:Person |
236 | grid-institutes:None | schema:alternateName | Department of Obstetrics and Gynaecology, Kärnsjukhuset, SE-541 85, Skövde, Sweden |
237 | ″ | ″ | Farmaservice, DK-2990, Nivå, Denmark |
238 | ″ | schema:name | Department of Obstetrics and Gynaecology, Kärnsjukhuset, SE-541 85, Skövde, Sweden |
239 | ″ | ″ | Farmaservice, DK-2990, Nivå, Denmark |
240 | ″ | rdf:type | schema:Organization |
241 | grid-institutes:grid.19477.3c | schema:alternateName | Norwegian School of Veterinary Science, also Ullevål University Hospital, Oslo, Norway |
242 | ″ | schema:name | Norwegian School of Veterinary Science, also Ullevål University Hospital, Oslo, Norway |
243 | ″ | rdf:type | schema:Organization |
244 | grid-institutes:grid.5510.1 | schema:alternateName | Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway |
245 | ″ | schema:name | Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway |
246 | ″ | rdf:type | schema:Organization |